Angelini Pharma has obtained development, manufacturing and commercialization rights to Ovid Therapeutics’ OV101 (gaboxadol), an investigational treatment for Angelman…
Articles by Patricia Inacio, PhD
Pinnacle Hill will start a second project aimed at the development of a treatment for Angelman syndrome based on…
The first patient has been dosed in GeneTx Biotherapeutics’ Phase 1/2 KIK-AS clinical trial evaluating…
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However,…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to candidate therapy NNZ-2591 to treat…
A potential treatment for Angelman syndrome, GTX-102, has been granted both orphan drug and rare pediatric disease designations by…
Neuren Pharmaceutical’s candidate NNZ-2591 has shown positive effects in a mouse model of Angelman syndrome, treating all symptoms…
The European Commission (EC) has granted orphan drug designation to Ovid Therapeutics’ OV101 for the treatment of Angelman syndrome.
Nonverbal Angelman syndrome patients can learn new information by exposure to repeated auditory stimuli, a new study shows. Measuring brain…
New data from Ovid Therapeutics’ Phase 2 STARS trial shows that treatment with oral candidate OV101 once daily at…